论文部分内容阅读
【目的】探讨注射型牛肺表面活性物质（珂立苏）联合经鼻同步间歇指令通气（NSIM V ）对新生儿肺透明膜病（HMD）的治疗效果及安全性。【方法】对37例HMD患儿予珂立苏联合NSIMV进行监护治疗，观察其疗效及并发症。【结果】PS联合NSIM V能明显改善HMD患儿呼吸、心率及血气各项指标，与治疗前比较差异有统计学意义（ P ＜0．05），且无严重并发症。【结论】珂立苏联合NSIM V治疗HMD安全有效，能减少气管插管比例及避免相关并发症，值得推广使用。“,”[Objective]To explore the efficacy and safety of pulmonary surfactant (PS) combined with nasal synchro-nized intermittent mandatory ventilation (Nsimv ) for the treatment of neonatal pulmonary hyaline membrane disease (HMD) .[Methods] A total of 37 pediatric patients with HMD were treated with Kelisu and Nsimv .The efficacy and complications were observed .[Results] PS combined with Nsimv could improve respiration ,heart rate and blood gas in-dexes of HMD patients ,and there was significant difference between before and after treatment ( P<0 .05) .No serious complication occurred .[Conclusion] PS combined with Nsimv for the treatment of HMD is safe and effective ,and can re-duce endotracheal intubation ratio and avoid the related complications .Therefore it is worth popularizing .